Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aao3003
Abstract: Dual inhibition of MDMX and MDM2 by an α-helical p53-stapled peptide (ALRN-6924) results in robust antitumor activity in acute myeloid leukemia. A new staple of leukemia treatment? As suggested by their name, tumor suppressor genes… read more here.
Keywords: mdmx mdm2; inhibition; mdmx; alrn 6924 ... See more keywords
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-0715
Abstract: Purpose: We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized, cell-permeating peptide that disrupts p53 inhibition by mouse double minute 2 (MDM2) and MDMX to induce cell-cycle arrest or apoptosis in TP53-wild-type (WT) tumors.… read more here.
Keywords: alrn 6924; alrn; trial alrn; arm ... See more keywords